Epigenomics AG (Epigenomics AG) Change In Payables And Accrued Expense : $0.00 Mil (TTM As of Jun. 2023)

View and export this data going back to . Start your Free Trial

What is Epigenomics AG Change In Payables And Accrued Expense?

Epigenomics AG's Change In Payables And Accrued Expense for the quarter that ended in Jun. 2023 was $0.00 Mil. It means Epigenomics AG's Accounts Payable & Accrued Expense stayed the same from Mar. 2023 to Jun. 2023 .

Epigenomics AG's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2022 was $0.00 Mil. It means Epigenomics AG's Accounts Payable & Accrued Expense stayed the same from Dec. 2021 to Dec. 2022 .

Epigenomics AG Change In Payables And Accrued Expense Historical Data

The historical data trend for Epigenomics AG's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Epigenomics AG Change In Payables And Accrued Expense Chart

Epigenomics AG Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

Epigenomics AG Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															-	-	-	-	-

Epigenomics AG Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Epigenomics AG Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Epigenomics AG's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Epigenomics AG (Epigenomics AG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Epigenomics AG (OTCPK:EPGNF) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

ECX:Germany

Address

Geneststrasse 5, Berlin, BB, DEU, 10829

Website

https://www.epigenomics.com

Epigenomics AG is a molecular diagnostics company, that focuses on developing and commercializing in vitro diagnostic liquid biopsy tests for the screening, early detection, and diagnosis of cancer. The company develops and markets procedures and devices for the production in quantity of particular epigenetic parameters such as DNA methylation patterns as well as the information technology bases necessary for their procurement and evaluation. It is engaged in the development of novel molecular diagnostic products for cancer. The company products include Epi proColon, Epi BiSKit, HCCBloodTest, and Epi proLung. The company operates in Europe, Asia, and North America, majority of its revenue derives from Asia.

Epigenomics AG (Epigenomics AG) Headlines

From GuruFocus

Encode Ideas, L.P. to host Virtual 1x1 Webinar with Epigenomics AG (ECX.DE, EPGNF) on Tuesday, July 28th at 10:30 AM ET

By ACCESSWIRE ACCESSWIRE • 07-23-2020